EGM
NBIX icon

Engineers Gate Manager’s Neurocrine Biosciences NBIX Stock Holding History

Engineers Gate Manager’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.09M Buy
18,361
+7,163
+64% +$1.06M 0.04% 509
2026
Q1 		$1.48M Sell
11,198
-1,122
-9% -$149K 0.02% 860
2025
Q4 		$1.75M Buy
12,320
+4,686
+61% +$679K 0.02% 758
2025
Q3 		$1.07M Buy
7,634
+2,242
+42% +$304K 0.01% 1118
2025
Q2 		$678K Buy
5,392
+2,273
+73% +$261K 0.01% 1330
2025
Q1 		$345K Sell
3,119
-15,847
-84% -$2.01M 0.01% 1632
2024
Q4 		$2.59M Sell
18,966
-57,656
-75% -$7.13M 0.05% 522
2024
Q3 		$8.83M Buy
76,622
+41,978
+121% +$5.75M 0.17% 151
2024
Q2 		$4.77M Buy
34,644
+17,542
+103% +$2.41M 0.11% 274
2024
Q1 		$2.36M Buy
17,102
+7,487
+78% +$1.02M 0.06% 419
2023
Q4 		$1.27M Sell
9,615
-13,205
-58% -$1.52M 0.04% 666
2023
Q3 		$2.57M Buy
22,820
+5,832
+34% +$614K 0.09% 291
2023
Q2 		$1.6M Sell
16,988
-734
-4% -$71.7K 0.06% 444
2023
Q1 		$1.79M Buy
17,722
+13,625
+333% +$1.42M 0.07% 343
2022
Q4 		$489K Buy
+4,097
New +$480K 0.03% 907
2022
Q3 		– Sell
-5,262
Closed -$513K – 1919
2022
Q2 		$513K Buy
5,262
+1,539
+41% +$142K 0.02% 1096
2022
Q1 		$349K Buy
3,723
+976
+36% +$82.7K 0.01% 1291
2021
Q4 		$234K Sell
2,747
-3,909
-59% -$360K 0.01% 1555
2021
Q3 		$638K Sell
6,656
-5,149
-44% -$486K 0.04% 738
2021
Q2 		$1.15M Buy
+11,805
New +$1.13M 0.07% 372
2020
Q4 		– Sell
-12,618
Closed -$1.21M – 1881
2020
Q3 		$1.21M Buy
12,618
+8,983
+247% +$1.04M 0.06% 518
2020
Q2 		$443K Buy
3,635
+929
+34% +$103K 0.02% 1007
2020
Q1 		$234K Sell
2,706
-21,399
-89% -$2.09M 0.02% 1177
2019
Q4 		$2.59M Buy
24,105
+18,635
+341% +$1.95M 0.11% 260
2019
Q3 		$493K Buy
+5,470
New +$511K 0.03% 789
2019
Q2 		– Sell
-2,400
Closed -$211K – 1302
2019
Q1 		$211K Buy
+2,400
New +$201K 0.01% 819

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Engineers Gate Manager's NBIX Position: Q2 2026 in Review

Engineers Gate Manager increased its Neurocrine Biosciences (NBIX) stake by 64% in Q2 2026, buying an estimated $1.06M and bringing the position to 18,361 shares worth $3.09M. The position accounts for 0.04% of the portfolio, ranked #509.

Engineers Gate Manager first reported a position in NBIX in Q1 2019 and has held it in 26 quarters since. The position peaked at $8.83M in Q3 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Engineers Gate Manager held 18,361 shares of Neurocrine Biosciences worth $3.09M as of Q2 2026.
  • Engineers Gate Manager bought 7,163 Neurocrine Biosciences shares in Q2 2026, an estimated $1.06M.
  • Neurocrine Biosciences made up 0.04% of Engineers Gate Manager's portfolio in Q2 2026, its #509 holding.
  • Engineers Gate Manager first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 26 quarters since.
  • Engineers Gate Manager's Neurocrine Biosciences position peaked at $8.83M in Q3 2024.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.